The spelling of the word "Bodals test" is straightforward when broken down phonetically. It is pronounced /ˈboʊdəlz tɛst/, with the stress on the first syllable of both "Bodals" and "test." The first part, "Bodals," is pronounced as "BOH-duhls" with the "o" sounding like the "o" in "go" and the "a" sounding like the "a" in "father." The second part, "test," is pronounced as "tɛst," with the "e" sounding like the "e" in "pen" and the "s" being unvoiced.
Bodal's test is a laboratory diagnostic procedure used to detect the presence of abnormal proteins in the blood, particularly in cases of multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells, which are a part of the immune system responsible for producing antibodies. Bodal's test is named after its developer, a French hematologist named Jean Bodal.
This test involves the creation of a gel made from agarose, a type of carbohydrate derived from seaweed. The agarose gel is placed in a tray, and a sample of the patient's blood serum is applied onto the gel. The gel is then subjected to an electrical charge, causing proteins in the serum to move across the gel based on their size and electrical charge.
By observing the migration pattern of the proteins, doctors can identify any abnormalities in their movement. In the case of multiple myeloma, a specific protein called M protein may migrate abnormally, forming a distinctive band or spike on the gel. The presence of this abnormal band can confirm the diagnosis of multiple myeloma or indicate the possibility of other related conditions.
Bodal's test is a valuable tool in diagnosing and monitoring multiple myeloma, as well as other conditions involving abnormal protein production. It can help healthcare professionals determine the appropriate treatment plan and assess disease progression.